

# Clinical Trials - Company Evaluation Report, 2025

<https://marketpublishers.com/r/CD7186F8342EEN.html>

Date: August 2025

Pages: 172

Price: US\$ 2,650.00 (Single User License)

ID: CD7186F8342EEN

## Abstracts

The clinical trial services Companies Quadrant is a comprehensive industry analysis that provides valuable insights into the global market for clinical trial services. This quadrant offers a detailed evaluation of key market players, technological advancements, product innovations, and emerging trends shaping the industry. MarketsandMarkets 360 Quadrants evaluated over 100 companies, of which the Top 19 EVA Films Companies were categorized and recognized as the quadrant leaders.

A clinical trial services is an electronic device that uses the mechanical resonance of a piezoelectric material-based vibrating crystal to generate an electric pulse of a specific frequency. The electrical signal generated by the crystal oscillator is used to keep track of time in quartz wristwatches, provide a stable clock signal for digital ICs, and stabilize the frequencies of radio transmitters and receivers. The oscillations generated by the crystal can be set or modified to generate the desired frequency signals according to application requirements. For the past few years, major players in the crystal oscillator market have adopted product launches and developments as their key strategies. Companies also adopt several other growth strategies, such as collaborations, acquisitions, and partnerships, to increase their market share.

The 360 Quadrant maps the clinical trial services companies based on criteria such as revenue, geographic presence, growth strategies, investments, and sales strategies for the market presence of the clinical trial services quadrant. The top criteria for product footprint evaluation included by service type (clinical trial management & monitoring services; laboratory services, including analytical testing and bioanalytical testing; patient recruitment & retention services; medical writing services; clinical trial supply & logistic services; safety & pharmacovigilance services; clinical trial data management services such as biostatistics and other data management services; consulting; and other service types) by phase (Phase I, Phase II, Phase III, & Phase IV) by MODALITY (small molecules, biologics, and medical devices & IVD) therapeutic area (oncology,

neurology, infectious diseases, cardiovascular system (CVS) disorders, metabolic disorders/endocrinology, immunological disorders, respiratory disorders, psychiatry, dermatology, hematology, ophthalmology, gastrointestinal diseases, genitourinary & women's health, and other therapeutic areas.) by Delivery Model (full-service outsourcing (FSO), functional service providers (FSP), and hybrid models), by STUDY Design (interventional and observational.) and END USER (large pharma-biotech companies, small & mid-sized pharma-biotech companies, CROs, medical device manufacturers, and other end users..)

### Key Players:

Key players operating in the clinical trial services IQVIA Inc. (US), Thermo Fisher Scientific Inc. (US), Fortrea (US), ICON Plc (Ireland), Syneos Health (US), Laboratory Corporation of America Holdings (US), Medpace (US), WuXi AppTec (China), Frontage Labs (US), Pharmaron (US), Tigermed (China), SGS Société Générale de Surveillance SA. (Switzerland), Eurofins Scientific (Luxembourg), Linical (Japan), and Parexel International Corporation (US), among others.

#### IQVIA Inc.

IQVIA is a major player in the clinical trials market, leveraging its advanced data analytics and global reach to drive drug development. The company's Connected Intelligence platform is instrumental in optimizing trial protocols and patient selection. Through its strategic partnerships with pharmaceutical companies and clinical technology vendors, IQVIA enhances industry-wide adoption and efficiency in clinical timelines.

#### ICON Plc

ICON Plc, headquartered in Ireland, offers a comprehensive range of clinical development services for pharmaceuticals, biotechnology, and medical devices. The integration of AI into ICON's service offerings improves data management and patient recruitment processes, reinforcing its market position. The company's commitment to innovation ensures its adaptability to evolving market dynamics.

#### Thermo Fisher Scientific Inc.

Thermo Fisher has strengthened its clinical research services significantly through its acquisition of PPD. This strategic move has expanded its market footprint, making it a leading provider for pharmaceutical and biotech companies globally. The company is notable for its extensive service portfolio and focus on geographic expansion to support diverse clientele.

## Contents

### 1 INTRODUCTION

#### 1.1 MARKET DEFINITION

#### 1.2 STAKEHOLDERS

### 2 EXECUTIVE SUMMARY

### 3 MARKET OVERVIEW

#### 3.1 INTRODUCTION

#### 3.2 MARKET DYNAMICS

##### 3.2.1 DRIVERS

3.2.1.1 Increasing focus on patient-centric trials (DCTs)

3.2.1.2 Increasing clinical trials for precision/personalized medicines supporting growth in clinical trial outsourcing

3.2.1.3 Rising R&D investments and patent cliff pressure driving growth in outsourcing clinical trial activities

3.2.1.4 Service flexibility offered by CROs for clinical development (FSP, FSO, Hybrid)

3.2.1.5 Technological integrations

##### 3.2.2 OPPORTUNITIES

3.2.2.1 Increased focus on pediatric clinical trials

3.2.2.2 Increasing regulatory requirements for increasing diversity in clinical trials

3.2.2.3 Growing role of real-world evidence in drug approvals

3.2.2.4 Expanding drug modalities (such as CGT, Tissue Engineering, Bispecific Abs) in clinical trials

##### 3.2.3 CHALLENGES

3.2.3.1 Cybersecurity or intellectual property concerns

3.2.3.2 Challenge of patient retention

3.2.3.3 Growing market competition

#### 3.3 MARKET TRENDS

##### 3.3.1 IN SILICO CLINICAL TRIALS

#### 3.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS

#### 3.5 VALUE CHAIN ANALYSIS

#### 3.6 ECOSYSTEM ANALYSIS

#### 3.7 TECHNOLOGY ANALYSIS

##### 3.7.1 KEY TECHNOLOGIES

- 3.7.1.1 Clinical trial management system (CTMS)
- 3.7.1.2 Electronic data capture (EDC) systems
- 3.7.1.3 Randomization and trial supply management (RTSM)
- 3.7.2 COMPLEMENTARY TECHNOLOGIES
  - 3.7.2.1 Telemedicine and wearable devices
  - 3.7.2.2 AI and ML integration
- 3.8 KEY CONFERENCES AND EVENTS, 2025–2026
- 3.9 PORTER'S FIVE FORCES ANALYSIS
  - 3.9.1 THREAT OF NEW ENTRANTS
  - 3.9.2 THREAT OF SUBSTITUTES
  - 3.9.3 BARGAINING POWER OF SUPPLIERS
  - 3.9.4 BARGAINING POWER OF BUYERS
  - 3.9.5 INTENSITY OF COMPETITIVE RIVALRY
- 3.10 IMPACT OF AI/GEN AI ON CLINICAL TRIAL SERVICES MARKET
  - 3.10.1 INTRODUCTION
  - 3.10.2 MARKET POTENTIAL FOR CLINICAL TRIALS
  - 3.10.3 AI USE CASES
  - 3.10.4 KEY COMPANIES IMPLEMENTING AI
  - 3.10.5 FUTURE OF GENERATIVE AI IN CLINICAL TRIAL ECOSYSTEM

## **4 COMPETITIVE LANDSCAPE**

- 4.1 OVERVIEW
- 4.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
- 4.3 REVENUE ANALYSIS
- 4.4 MARKET SHARE ANALYSIS, 2024
- 4.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  - 4.5.1 STARS
  - 4.5.2 EMERGING LEADERS
  - 4.5.3 PERVASIVE PLAYERS
  - 4.5.4 PARTICIPANTS
  - 4.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    - 4.5.5.1 Company footprint
    - 4.5.5.2 Region footprint
    - 4.5.5.3 Service type footprint
    - 4.5.5.4 Phase footprint
- 4.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  - 4.6.1 PROGRESSIVE COMPANIES
  - 4.6.2 RESPONSIVE COMPANIES

4.6.3 DYNAMIC COMPANIES

4.6.4 STARTING BLOCKS

4.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024

4.6.5.1 Detailed list of key startups/SMEs

4.6.5.2 Competitive benchmarking of startups/SMEs

4.7 COMPANY VALUATION AND FINANCIAL METRICS

4.8 BRAND/SERVICE COMPARISON

4.9 COMPETITIVE SCENARIO

4.9.1 SERVICE LAUNCHES

4.9.2 DEALS

4.9.3 EXPANSIONS

## **5 COMPANY PROFILES**

5.1 KEY PLAYERS

5.1.1 IQVIA INC.

5.1.1.1 Business overview

5.1.1.2 Services offered

5.1.1.3 Recent developments

5.1.1.3.1 Service launches

5.1.1.3.2 Deals

5.1.1.3.3 Expansions

5.1.1.4 MnM view

5.1.1.4.1 Right to win

5.1.1.4.2 Strategic choices

5.1.1.4.3 Weaknesses and competitive threats

5.1.2 ICON PLC

5.1.2.1 Business overview

5.1.2.2 Services offered

5.1.2.3 Recent developments

5.1.2.3.1 Service launches

5.1.2.3.2 Deals

5.1.2.4 MnM view

5.1.2.4.1 Right to win

5.1.2.4.2 Strategic choices

5.1.2.4.3 Weaknesses and competitive threats

5.1.3 THERMO FISHER SCIENTIFIC INC.

5.1.3.1 Business overview

5.1.3.2 Services offered

- 5.1.3.3 Recent developments
  - 5.1.3.3.1 Service launches
  - 5.1.3.3.2 Deals
  - 5.1.3.3.3 Expansions
- 5.1.3.4 MnM view
  - 5.1.3.4.1 Right to win
  - 5.1.3.4.2 Strategic choices
  - 5.1.3.4.3 Weaknesses and competitive threats
- 5.1.4 FORTREA
  - 5.1.4.1 Business overview
  - 5.1.4.2 Services offered
  - 5.1.4.3 Recent developments
    - 5.1.4.3.1 Service launches
    - 5.1.4.3.2 Deals
    - 5.1.4.3.3 Expansions
  - 5.1.4.4 MnM view
    - 5.1.4.4.1 Right to win
    - 5.1.4.4.2 Strategic choices
    - 5.1.4.4.3 Weaknesses and competitive threats
- 5.1.5 SYNEOS HEALTH
  - 5.1.5.1 Business overview
  - 5.1.5.2 Services offered
  - 5.1.5.3 Recent developments
    - 5.1.5.3.1 Service launches
    - 5.1.5.3.2 Deals
  - 5.1.5.4 MnM view
    - 5.1.5.4.1 Right to win
    - 5.1.5.4.2 Strategic choices
    - 5.1.5.4.3 Weaknesses and competitive threats
- 5.1.6 LABORATORY CORPORATION OF AMERICA HOLDINGS
  - 5.1.6.1 Business overview
  - 5.1.6.2 Services offered
  - 5.1.6.3 Recent developments
    - 5.1.6.3.1 Service launches
    - 5.1.6.3.2 Deals
    - 5.1.6.3.3 Expansions
  - 5.1.6.4 MnM view
    - 5.1.6.4.1 Right to win
    - 5.1.6.4.2 Strategic choices

- 5.1.6.4.3 Weaknesses and competitive threats
- 5.1.7 MEDPACE
  - 5.1.7.1 Business overview
  - 5.1.7.2 Services offered
- 5.1.8 WUXI APPTec
  - 5.1.8.1 Business overview
  - 5.1.8.2 Services offered
  - 5.1.8.3 Recent developments
    - 5.1.8.3.1 Deals
- 5.1.9 FRONTAGE LABS
  - 5.1.9.1 Business overview
  - 5.1.9.2 Services offered
  - 5.1.9.3 Recent developments
    - 5.1.9.3.1 Deals
    - 5.1.9.3.2 Expansions
- 5.1.10 PHARMARON
  - 5.1.10.1 Business overview
  - 5.1.10.2 Services offered
- 5.1.11 TIGERMED
  - 5.1.11.1 Business overview
  - 5.1.11.2 Services offered
  - 5.1.11.3 Recent developments
    - 5.1.11.3.1 Service approvals
    - 5.1.11.3.2 Deals
- 5.1.12 SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA
  - 5.1.12.1 Business overview
  - 5.1.12.2 Services offered
- 5.1.13 EUROFINS SCIENTIFIC
  - 5.1.13.1 Business overview
  - 5.1.13.2 Services offered
- 5.1.14 LINICAL
  - 5.1.14.1 Business overview
  - 5.1.14.2 Services offered
  - 5.1.14.3 Recent developments
    - 5.1.14.3.1 Deals
    - 5.1.14.3.2 Expansions
- 5.1.15 PAREXEL INTERNATIONAL CORPORATION
  - 5.1.15.1 Business overview
  - 5.1.15.2 Services offered

### 5.1.15.3 Recent developments

#### 5.1.15.3.1 Service launches

#### 5.1.15.3.2 Deals

#### 5.1.15.3.3 Expansions

## 5.2 OTHER PLAYERS

### 5.2.1 WORLDWIDE CLINICAL TRIALS

### 5.2.2 PROPHARMA

### 5.2.3 NOVOTECH

### 5.2.4 PSI

### 5.2.5 ALLUCENT

### 5.2.6 PREMIER RESEARCH

### 5.2.7 CAIDYA

### 5.2.8 ERGOMED GROUP

### 5.2.9 CLARIO

### 5.2.10 PRECISION MEDICINE GROUP, LLC.

### 5.2.11 ADVANCED CLINICAL

### 5.2.12 EPS HOLDINGS, INC.

### 5.2.13 GUIRES INC. (PEPGRA)

### 5.2.14 KCR S.A.

## 6 APPENDIX

### 6.1 RESEARCH METHODOLOGY

#### 6.1.1 RESEARCH DATA

##### 6.1.1.1 Secondary data

##### 6.1.1.2 Primary data

#### 6.1.2 RESEARCH ASSUMPTIONS

#### 6.1.3 RESEARCH LIMITATIONS

### 6.2 COMPANY EVALUATION MATRIX: METHODOLOGY

### 6.3 AUTHOR DETAILS

## List Of Tables

### LIST OF TABLES

TABLE 1 CLINICAL TRIAL SERVICES MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS

TABLE 2 CLINICAL TRIAL SERVICES MARKET: ROLE OF COMPANIES IN ECOSYSTEM

TABLE 3 CLINICAL TRIAL SERVICES MARKET: KEY CONFERENCES AND EVENTS, 2025–2026

TABLE 4 CLINICAL TRIAL SERVICES MARKET: PORTER'S FIVE FORCES ANALYSIS

TABLE 5 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CLINICAL TRIAL SERVICES MARKET, JANUARY 2021–JANUARY 2025

TABLE 6 CLINICAL TRIAL SERVICES MARKET: DEGREE OF COMPETITION, 2024

TABLE 7 CLINICAL TRIAL SERVICES MARKET: REGION FOOTPRINT

TABLE 8 CLINICAL TRIAL SERVICES MARKET: SERVICE TYPE FOOTPRINT

TABLE 9 CLINICAL TRIAL SERVICES MARKET: PHASE FOOTPRINT

TABLE 10 CLINICAL TRIAL SERVICES MARKET: DETAILED LIST OF KEY STARTUP/SMES

TABLE 11 CLINICAL TRIAL SERVICES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES

TABLE 12 CLINICAL TRIAL SERVICES MARKET: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025

TABLE 13 CLINICAL TRIAL SERVICES MARKET: DEALS, JANUARY 2021–JANUARY 2025

TABLE 14 CLINICAL TRIAL SERVICES MARKET: EXPANSIONS, JANUARY 2021–JANUARY 2025

TABLE 15 IQVIA INC.: COMPANY OVERVIEW

TABLE 16 IQVIA INC.: SERVICES OFFERED

TABLE 17 IQVIA INC.: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025

TABLE 18 IQVIA INC.: DEALS, JANUARY 2021–JANUARY 2025

TABLE 19 IQVIA INC.: EXPANSIONS, JANUARY 2021–JANUARY 2025

TABLE 20 ICON PLC: COMPANY OVERVIEW

TABLE 21 ICON PLC: SERVICES OFFERED

TABLE 22 ICON PLC: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025

TABLE 23 ICON PLC: DEALS, JANUARY 2021–JANUARY 2025

TABLE 24 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW

TABLE 25 THERMO FISHER SCIENTIFIC INC.: SERVICES OFFERED

TABLE 26 THERMO FISHER SCIENTIFIC INC.: SERVICE LAUNCHES, JANUARY

2021–JANUARY 2025

TABLE 27 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021–JANUARY 2025

TABLE 28 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2021–JANUARY 2025

TABLE 29 FORTREA: COMPANY OVERVIEW

TABLE 30 FORTREA: SERVICES OFFERED

TABLE 31 FORTREA: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025

TABLE 32 FORTREA: DEALS, JANUARY 2021–JANUARY 2025

TABLE 33 FORTREA: EXPANSIONS, JANUARY 2021–JANUARY 2025

TABLE 34 SYNEOS HEALTH: COMPANY OVERVIEW

TABLE 35 SYNEOS HEALTH: SERVICES OFFERED

TABLE 36 SYNEOS HEALTH: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025

TABLE 37 SYNEOS HEALTH: DEALS, JANUARY 2021–JANUARY 2025

TABLE 38 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY OVERVIEW

TABLE 39 LABORATORY CORPORATION OF AMERICA HOLDINGS: SERVICES OFFERED

TABLE 40 LABORATORY CORPORATION OF AMERICA HOLDINGS: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025

TABLE 41 LABORATORY CORPORATION OF AMERICA HOLDINGS: DEALS, JANUARY 2021–JANUARY 2025

TABLE 42 LABORATORY CORPORATION OF AMERICA HOLDINGS: EXPANSIONS, JANUARY 2021–JANUARY 2025

TABLE 43 MEDPACE: COMPANY OVERVIEW

TABLE 44 MEDPACE: SERVICES OFFERED

TABLE 45 WUXI APPTTEC: COMPANY OVERVIEW

TABLE 46 WUXI APPTTEC: SERVICES OFFERED

TABLE 47 WUXI APPTTEC: DEALS, JANUARY 2021–JANUARY 2025

TABLE 48 FRONTAGE LABS: COMPANY OVERVIEW

TABLE 49 FRONTAGE LABS: SERVICES OFFERED

TABLE 50 FRONTAGE LABS: DEALS, JANUARY 2021–JANUARY 2025

TABLE 51 FRONTAGE LABS: EXPANSIONS, JANUARY 2021–JANUARY 2025

TABLE 52 PHARMARON: COMPANY OVERVIEW

TABLE 53 PHARMARON: SERVICES OFFERED

TABLE 54 TIGERMED: COMPANY OVERVIEW

TABLE 55 TIGERMED: SERVICES OFFERED

TABLE 56 TIGERMED: SERVICE APPROVALS, JANUARY 2021–JANUARY 2025

TABLE 57 TIGERMED: DEALS, JANUARY 2021–JANUARY 2025

TABLE 58 SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA: COMPANY OVERVIEW

TABLE 59 SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA.: SERVICES OFFERED

TABLE 60 EUROFINS SCIENTIFIC: COMPANY OVERVIEW

TABLE 61 EUROFINS SCIENTIFIC: SERVICES OFFERED

TABLE 62 LINICAL: COMPANY OVERVIEW

TABLE 63 LINICAL: SERVICES OFFERED

TABLE 64 LINICAL: DEALS, JANUARY 2021–JANUARY 2025

TABLE 65 LINICAL: EXPANSIONS, JANUARY 2021–JANUARY 2025

TABLE 66 PAREXEL INTERNATIONAL CORPORATION: COMPANY OVERVIEW

TABLE 67 PAREXEL INTERNATIONAL CORPORATION: SERVICES OFFERED

TABLE 68 PAREXEL INTERNATIONAL CORPORATION: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025

TABLE 69 PAREXEL INTERNATIONAL CORPORATION: DEALS, JANUARY 2021–JANUARY 2025

TABLE 70 PAREXEL INTERNATIONAL CORPORATION: EXPANSIONS, JANUARY 2021–JANUARY 2025

TABLE 71 WORLDWIDE CLINICAL TRIALS: COMPANY OVERVIEW

TABLE 72 PROPHARMA: COMPANY OVERVIEW

TABLE 73 NOVOTECH: COMPANY OVERVIEW

TABLE 74 PSI: COMPANY OVERVIEW

TABLE 75 ALLUCENT: COMPANY OVERVIEW

TABLE 76 PREMIER RESEARCH: COMPANY OVERVIEW

TABLE 77 CAIDYA: COMPANY OVERVIEW

TABLE 78 ERGOMED GROUP: COMPANY OVERVIEW

TABLE 79 CLARIO: COMPANY OVERVIEW

TABLE 80 PRECISION MEDICINE GROUP, LLC: COMPANY OVERVIEW

TABLE 81 ADVANCED CLINICAL: COMPANY OVERVIEW

TABLE 82 EPS HOLDINGS, INC.: COMPANY OVERVIEW

TABLE 83 GUIRES INC. (PEPGRA): COMPANY OVERVIEW

TABLE 84 KCR S.A.: COMPANY OVERVIEW

TABLE 85 RISK ASSESSMENT

## List Of Figures

### LIST OF FIGURES

FIGURE 1 CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE, 2025 VS. 2030 (USD MILLION)

FIGURE 2 CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA, 2025 VS. 2030 (USD MILLION)

FIGURE 3 CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL, 2024 (USD MILLION)

FIGURE 4 CLINICAL TRIAL SERVICES MARKET, BY MODALITY, 2024 (USD MILLION)

FIGURE 5 CLINICAL TRIAL SERVICES MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)

FIGURE 6 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN CLINICAL TRIAL SERVICES MARKET DURING FORECAST PERIOD

FIGURE 7 DRIVERS, OPPORTUNITIES, AND CHALLENGES IN CLINICAL TRIAL SERVICES MARKET

FIGURE 8 R&D SPEND OF LARGE PHARMACEUTICAL COMPANIES, 2014–2023 (USD BILLION)

FIGURE 9 BIOSIMILAR APPROVALS IN US, 2015–2024

FIGURE 10 NUMBER OF CLINICAL TRIALS FOR VARIOUS MODALITIES

FIGURE 11 TRENDS/DISRUPTIONS INFLUENCING CUSTOMER BUSINESS

FIGURE 12 CLINICAL TRIAL SERVICES MARKET: VALUE CHAIN ANALYSIS

FIGURE 14 CLINICAL TRIAL SERVICES MARKET: PORTER'S FIVE FORCES ANALYSIS

FIGURE 15 CLINICAL TRIAL SERVICES MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2022–2024 (USD MILLION)

FIGURE 16 CLINICAL TRIAL SERVICES MARKET SHARE ANALYSIS, 2024

FIGURE 17 CLINICAL TRIAL SERVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024

FIGURE 18 CLINICAL TRIAL SERVICES MARKET: COMPANY FOOTPRINT

FIGURE 19 CLINICAL TRIAL SERVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024

FIGURE 20 CLINICAL TRIAL SERVICES MARKET: YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2024

FIGURE 21 CLINICAL TRIAL SERVICES MARKET: EV/EBITDA OF KEY VENDORS, 2024

FIGURE 22 CLINICAL TRIAL SERVICES MARKET: BRAND/SERVICE COMPARISON

FIGURE 23 IQVIA INC.: COMPANY SNAPSHOT (2024)

FIGURE 24 ICON PLC: COMPANY SNAPSHOT (2023)  
FIGURE 25 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)  
FIGURE 26 FORTREA: COMPANY SNAPSHOT (2023)  
FIGURE 27 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2023)  
FIGURE 28 MEDPACE: COMPANY SNAPSHOT (2024)  
FIGURE 29 WUXI APPTTEC: COMPANY SNAPSHOT (2023)  
FIGURE 30 FRONTAGE LABS: COMPANY SNAPSHOT (2023)  
FIGURE 31 PHARMARON: COMPANY SNAPSHOT (2023)  
FIGURE 32 TIGERMED: COMPANY SNAPSHOT (2023)  
FIGURE 33 SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA: COMPANY SNAPSHOT (2023)  
FIGURE 34 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2024)  
FIGURE 35 LINICAL: COMPANY SNAPSHOT (2023)  
FIGURE 36 RESEARCH DESIGN

## I would like to order

Product name: Clinical Trials - Company Evaluation Report, 2025

Product link: <https://marketpublishers.com/r/CD7186F8342EEN.html>

Price: US\$ 2,650.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CD7186F8342EEN.html>